March 21, 2019
Webinar
As recognized by the U.S. Food and Drug Administration (FDA), “[b]iological products often represent the cutting edge of biomedical research.” While most small-molecule drugs are chemically synthesized and have known structures, most biological products are produced using biotechnological methods and have complex structures that are not easily identified or characterized. Reflective of these complexities, patent law for biological products continues to evolve, with growing numbers of patents for biological products are being prosecuted, challenged in post-grant proceedings before the U.S. Patent and Trademark Office (USPTO), and litigated under the Biologics Price Competition and Innovation Act (BPCIA).
Our panel will discuss the evolving law for biological product patents, including:
Moderator:
Thomas J. Sullivan
Speakers:
Shana K. Cyr, Ph.D.
Mark J. Feldstein, Ph.D.
Date:
Thursday, March 21, 2019
Time:
10:00 - 11:00 a.m. PDT
1:00 - 2:00 p.m. EDT
7:00 - 8:00 p.m. CEST
Scheduling Conflict? Finnegan records all hosted webinars. To view the recorded program, simply register for the webinar and you will receive an access link shortly after the live program is complete.
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.